Revolution Medicines Appoints Eric T. Schmidt, Ph.D. and Peter Svennilson to its Board of Directors

REDWOOD CITY, Calif., June 18, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced the appointments of Eric T. Schmidt, Ph.D., and Peter Svennilson to its board of directors. Dr. Schmidt and Mr. Svennilson are widely respected executives with extensive Wall Street and financial markets experience in the biopharmaceutical industry. Mr. Svennilson was appointed to fill the vacancy created by the resignation of Larry Lasky, Ph.D., who stepped down from the board of directors and will continue supporting the company as a scientific advisor.

“Eric and Peter will each strengthen our board’s financial expertise as Revolution Medicines continues maturing as a public company. In particular, Eric brings deep Wall Street insight from his tenure as a highly regarded sell-side biotechnology analyst and more recently as the chief financial officer of Allogene Therapeutics, a leading cell therapy company. Similarly, Peter brings considerable financial and transactional expertise based on his career as an investment banker, founder and a managing partner of The Column Group, and director for multiple successful biotechnology companies,” said Mark A. Goldsmith, M.D., Ph.D., chairman, chief executive officer and president of Revolution Medicines. “We look forward to the positive impact we expect both of these accomplished individuals will have as we continue to build on our company’s momentum. We appreciate Larry’s service on our board during our formative years, and we are pleased he will continue to draw from his vast scientific knowledge on our behalf.”

Dr. Schmidt currently serves as the chief financial officer of Allogene Therapeutics, a clinical-stage biotechnology company pioneering the development of allogeneic cell therapies for cancer. Previously, he was managing director and senior biotechnology analyst at Cowen and Company. During his two decades at Cowen, he was a highly trusted industry analyst whose work was recognized in polls conducted by The Wall Street Journal, Reuters, Alpha Magazine, and Institutional Investor. Prior to joining Cowen in 1998, Dr. Schmidt was vice president and research analyst covering the biotechnology sector at UBS Securities. Dr. Schmidt holds a bachelor’s degree in chemistry from the University of Pennsylvania and a Ph.D. in biochemistry from the Massachusetts Institute of Technology, where he serves on the visiting committee for the department of biology. He also serves on the board of directors for Relmada Therapeutics, Inc.